Full-Year Revenue Growth
FY2025 revenue of $6.2B, up 5.3% underlying (6.1% reported), ahead of guidance; 2022–2025 revenue CAGR of 5.7%.
Strong Q4 Performance
Q4 revenue of $1.7B, up 6.2% underlying and 8.3% reported (210 bps FX tailwind); average daily sales growth of 4.5% and broad-based regional growth (U.S. +5.6%, other established +7.2%, emerging +6.4%).
Margin Expansion and Trading Profit
Trading profit rose to $1.2B for the year (+$162M year-on-year) and trading margin expanded 160 basis points to 19.7% in FY2025 (gross margin 70.9%, +60 bps).
Cash Generation and Returns
Free cash flow of $840M, up 52.5% year-on-year and well ahead of initial guidance (> $600M); net debt $2.76B with leverage ~1.7x adjusted net debt/EBITDA; ROIC improved to 8.3% (9.9% excluding portfolio rationalization).
Operational Progress and Cost Savings
Cumulative efficiency savings of $280M achieved to end-2025 against a $325–375M by-2027 target; 160 bps FY25 margin expansion driven by enterprise-wide cost savings, manufacturing optimization, productivity and portfolio rationalization; group days sales inventory reduced materially (group DSI down 21 days excl. rationalization, 51 days incl.).
Innovation-led Growth
Over 60% of 2025 growth came from products launched in the last five years; 44 product launches over the last 3 years and guidance to launch 16 products in 2026; record CORI placements globally with 45% of CORI placements in ASCs and CORI-associated accounts showing Knee growth ~850 bps higher.
Portfolio and Capital Actions
Completed $500M share buyback in H2 2025; adjusted EPS grew 21% to $1.02 (benefitting from buyback); full-year dividend proposed +4.3% to $0.391; announced acquisition of Integrity Orthopaedics (up to $450M) to strengthen shoulder/rotator cuff franchise.